Literature DB >> 23755024

Diagnostic Criteria in Attention Deficit Hyperactivity Disorder - Changes in DSM 5.

Sarah Steinau1.   

Abstract

Entities:  

Year:  2013        PMID: 23755024      PMCID: PMC3667245          DOI: 10.3389/fpsyt.2013.00049

Source DB:  PubMed          Journal:  Front Psychiatry        ISSN: 1664-0640            Impact factor:   4.157


× No keyword cloud information.
Attention deficit hyperactivity disorder (ADHD) is the most common neurobehavioral disorder in childhood, affecting large numbers of children throughout the world. Because of the knowledge evolved from ADHD research, today's challenges are vast, including changes in terminology, fears of over-diagnosis, and over-medication of children. What began as a case description, has now evolved in clinical trials, leading from observations of behavior to advances in neuroscience. The biggest challenge remains in the correct diagnosis of ADHD, though. With a worldwide prevalence of approximately 5%, ADHD is very common (Polanczyk et al., 2007). ADHD in the United States even shows a prevalence among 8- to 15-years-olds of 8.7% and only a third of the ADHD patients have been treated consistently during the past year (Froehlich et al., 2007). In another age group (18- to 44-year-olds) the prevalence is about 4.4% (Kessler et al., 2006). Male patients are six times more often diagnosed with ADHD in childhood than female patients and three times more often in the adolescence. The prevalence seems to be equivalent in all levels of IQ and socioeconomic status (Gaub and Carlson, 1997; Levy et al., 1997; Smalley et al., 2000; Pastor and Reuben, 2008). The core symptoms of ADHD in DSM-IV-TR criteria (American Psychiatric Association, 2000) include inattention on the one hand and hyperactivity and impulsivity on the other hand, both having to be consistent to a degree that is maladaptive and inconsistent with developmental level, e.g., a 3-year-old's behavior is to be expected different from an 8-year-old's behavior. Additional criteria include the chronicity of ADHD symptoms, meaning that there has to be a persistence of symptoms at least for 6 months, pervasiveness of ADHD symptoms (ADHD symptoms have to be present in different settings and locations, or at least in more than one location, e.g., family, community, workplace), some hyperactive-impulsive or inattentive symptoms must have been present before the age of 7 years and there must be clear evidence of interference with developmentally appropriate social, academic, or occupational functioning, e.g., you may have one of the symptoms, but if it is not impairing you or interfering with your functioning, a diagnosis cannot be made. At last but not least, the disturbance does not occur exclusively during the course of other serious mental disorders (e.g., pervasive developmental disorder/autism, schizophrenia, other psychotic disorder). In the current DSM, there are three different ways of diagnosing ADHD. There is the combined type, e.g., both core symptoms are met for the past 6 months; there is the predominantly inattentive type and finally the predominantly hyperactive-impulsive type. But what are the strengths of DSM-IV criteria? The committee of experts that has developed the DSM-IV criteria catalog clearly uses rigorous and empirically derived criteria, has looked at all rating scales for diagnosing ADHD and has reviewed the ADHD literature. Additionally, the impairment criterion has been given greater emphasis in the past few years. Nevertheless there are certain weaknesses and controversies of DSM-IV criteria and it is important to have a second look: the age of onset criterion may not be justified (the age of 7 years does seem very restrictive), diagnostic item sets may be inappropriate for different developmental periods (e.g., not being able to sit quietly in a chair does not seem to be the right diagnostic item set for an adult, he does not need to listen or doesn't want to), diagnostic thresholds may not apply to older age groups (>16 years), there is no gender distinction in diagnostic thresholds and there is no lower age limit defined (<4 years). So what are potential changes in DSM 5 criteria (American Psychiatric Association, 2013)? For a start, the age onset criterion shall be increased from 7 years of age to 12 years of age. Then there is the intent to contextualize and illustrate diagnostic item sets to fit lifespan (e.g., inattention in a child versus an adolescent versus an adult). Additionally, there are up to four new criteria for impulsivity (there have been only three dimensions compared to inattention or hyperactivity). And finally, the number of criteria needed for adolescents and adults is likely to be revised, for data has suggested two to three from all three dimensions (subtypes for inattention, hyperactivity, and impulsivity) would be best, which will probably increase the prevalence dramatically.
  7 in total

1.  Gender differences in ADHD: a meta-analysis and critical review.

Authors:  M Gaub; C L Carlson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-08       Impact factor: 8.829

Review 2.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis.

Authors:  Guilherme Polanczyk; Maurício Silva de Lima; Bernardo Lessa Horta; Joseph Biederman; Luis Augusto Rohde
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

3.  Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study.

Authors:  F Levy; D A Hay; M McStephen; C Wood; I Waldman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-06       Impact factor: 8.829

4.  Familial clustering of symptoms and disruptive behaviors in multiplex families with attention-deficit/hyperactivity disorder.

Authors:  S L Smalley; J J McGough; M Del'Homme; J NewDelman; E Gordon; T Kim; A Liu; J T McCracken
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-09       Impact factor: 8.829

5.  Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children.

Authors:  Tanya E Froehlich; Bruce P Lanphear; Jeffery N Epstein; William J Barbaresi; Slavica K Katusic; Robert S Kahn
Journal:  Arch Pediatr Adolesc Med       Date:  2007-09

6.  The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Lenard Adler; Russell Barkley; Joseph Biederman; C Keith Conners; Olga Demler; Stephen V Faraone; Laurence L Greenhill; Mary J Howes; Kristina Secnik; Thomas Spencer; T Bedirhan Ustun; Ellen E Walters; Alan M Zaslavsky
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 18.112

7.  Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006.

Authors:  Patricia N Pastor; Cynthia A Reuben
Journal:  Vital Health Stat 10       Date:  2008-07
  7 in total
  8 in total

1.  Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol.

Authors:  Debora Areces; Marisol Cueli; Trinidad García; Paloma González-Castro; Celestino Rodríguez
Journal:  J Vis Exp       Date:  2018-04-01       Impact factor: 1.355

2.  Assessment of adult attention-deficit/hyperactivity disorder.

Authors:  Venkat Bhat; Joel Paris
Journal:  J Psychiatry Neurosci       Date:  2014-03       Impact factor: 6.186

Review 3.  A systematic review of transcranial direct current stimulation effects in attention-deficit/hyperactivity disorder.

Authors:  Camila Cosmo; Melany DiBiasi; Vania Lima; Luanda Collange Grecco; Mauro Muszkat; Noah S Philip; Eduardo Pondé de Sena
Journal:  J Affect Disord       Date:  2020-07-14       Impact factor: 4.839

4.  Development of a peptide targeting dopamine transporter to improve ADHD-like deficits.

Authors:  Terence K Y Lai; Ping Su; Hailong Zhang; Fang Liu
Journal:  Mol Brain       Date:  2018-11-09       Impact factor: 4.041

5.  Effects of Iron Supplementation on Attention Deficit Hyperactivity Disorder in Children Treated with Methylphenidate.

Authors:  Sepehr Tohidi; Elham Bidabadi; Mohammad-Javad Khosousi; Melika Amoukhteh; Maryam Kousha; Parham Mashouf; Tamkin Shahraki
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-11-30       Impact factor: 2.582

6.  PLS-DA Model for the Evaluation of Attention Deficit and Hyperactivity Disorder in Children and Adolescents through Blood Serum FTIR Spectra.

Authors:  Gulce Ogruc Ildiz; Ahmet Karadag; Ersin Kaygisiz; Rui Fausto
Journal:  Molecules       Date:  2021-06-03       Impact factor: 4.411

7.  An objective measure of hyperactivity aspects with compressed webcam video.

Authors:  Thomas Wehrmann; Jörg Michael Müller
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2015-09-10       Impact factor: 3.033

8.  Utility of medical record diagnostic codes to ascertain attention-deficit/hyperactivity disorder and learning disabilities in populations of children.

Authors:  Yu Shi; Phillip J Schulte; Andrew C Hanson; Michael J Zaccariello; Danqing Hu; Sheri Crow; Randall P Flick; David O Warner
Journal:  BMC Pediatr       Date:  2020-11-07       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.